Clarivate Unveils the 2025 Journal Citation Reports
Only journals that have met the rigorous quality standards for inclusion in the Web of Science Core Collection are featured within the Journal Citation Reports, which ensures users can confidently rely on the information and descriptive data provided. The annual reports provide a rich array of publisher–neutral data, metrics, and analysis to enhance user understanding of journal performance, including the widely recognized Journal Impact Factor (JIF) and the Journal Citation Indicator.
Key highlights for the 2025 release:
The JCR includes data from a total of 22,249 journals across 254 categories
Over 6,200 of these were published via gold open access
Scholarly journals from 111 countries are recognized and receive a JIF, including 14,591 in the sciences and 7,559 in the social sciences, as well as 3,368 journals in the arts and humanities
618 journals receive a JIF for the first time
This year's release excludes citations to and from retracted content when calculating the JIF numerator, ensuring that citations from retracted articles do not contribute to the numerical value of the JIF. However, retracted articles will still be included in the article count (JIF denominator), maintaining transparency and accountability. This policy affects 1% of journals.
Dr. Nandita Quaderi, Senior Vice President & Editor-in-Chief, Web of Science, Clarivate, said: "We are proud to remain true to our heritage while adapting to changes in the scholarly landscape. As we celebrate the 50th anniversary of the JCR, we are embracing our founder Eugene Garfield's vision and looking to the future, reinforcing our dedication to maintaining the integrity of the scientific record and continuing our journey towards a more equitable, transparent and trustworthy scholarly ecosystem."
Emmanuel Thiveaud, Senior Vice President, Research and Analytics, Academia & Government at Clarivate said: "We are excited to present the 2025 edition of the Journal Citation Reports, which continues to serve as a vital tool for the global research community. These valuable data and insights empower researchers and institutions to make informed decisions, fostering the advancement of knowledge and innovation."
To explore all available data, metrics and analysis visit the Journal Citation Reports.
For more detailed information on this year's changes, please see our blog.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
10 hours ago
- Cision Canada
Rocket Science Health Secures U.S Patent for Precision Intranasal Drug Delivery Platform
Patent covers a method of targeted drug delivery to the brain and central nervous system via subregions of the intranasal cavity Builds on recent corporate milestones and sets the stage for future strategic partnerships Advances Rocket Science Health's progression towards broader clinical applications VICTORIA, BC, July 30, 2025 /CNW/ - Rocket Science Health Corp., a Canadian healthcare technology company focused on precision drug delivery for brain therapeutics and vaccines, today announced it has secured U.S. Patent No. 12,343,489 from the United States Patent and Trademark Office for its investigational precision intranasal drug delivery device. The patent covers a method of targeted delivery of therapeutic compositions to subregions of the intranasal cavity, including the olfactory, dispensed from a vantage point that is essential for maximizing on-target and avoiding off-target delivery of drugs. "Getting drugs to the brain is one of medicine's hardest problems and our proprietary technology is designed to address that challenge – not just for brain delivery, but also for vaccines and other treatments that need more targeted approaches. It's not rocket science, but a simple drug delivery device that has the potential to make sophisticated drugs work, while broadening access to live-saving treatments," said Sohier Hall, President of Rocket Science Health. "The granting of these key patents is an important milestone on our journey to scale and accelerate the delivery of next-generation brain and central nervous system treatments, with the goal of initiating human clinical trials with our device in the near future." The upper nasal cavity offers a unique access point to the brain and central nervous system that can optimize the brain's exposure to drug therapies, accelerate the onset of action, reduce drug doses, improve the accuracy of delivery, and potentially improve health outcomes for millions of patients. However, commercially available nasal spray devices can only deliver a fraction of their dose volume to the olfactory region due to the anatomical characteristics of the nasal cavity. At the same time, nearly all small and large molecule drug therapies approved by the FDA cannot enter the central nervous system when taken through other, traditional routes of administration. Initial peer-reviewed research and in-human imaging studies have validated Rocket Science Health's patented technology and demonstrated precise, repeatable drug deposition to subregions of the intranasal cavity. This technology is compatible with delicate drug formulations, including lipid nanoparticles (LNPs), biologics, peptides, and can handle a range of viscosities. The Company is evaluating licensing of its technology to developers where precision delivery is a potential factor for success in their pending clinical trial. The intellectual property applies to both next-generation therapies or reestablishing existing molecules with greater effect and patent ability. With strong intellectual property, validated in-human results, and industry-leading execution partners in place, Rocket Science is well-positioned to advance toward broader clinical applications in brain-targeted drug delivery. For more information on Rocket Science Health, visit About Rocket Science Health: Rocket Science Health, founded by Canadian business leader Kenneth Irving, develops precision drug delivery technologies focused on brain-targeted therapeutics and vaccines. Our needle-free intranasal device enables non-clinical self-administration for at-home care, emergency rescue, and mass immunization. Its fluidics are specifically engineered for today's delicate biologics and dose-dependent drugs. As a team, we are driven to create innovations that expand access to care—especially for under-resourced communities and for individuals who face physical, cognitive, or challenging care environments where thoughtful design can improve health outcomes.
Cision Canada
10 hours ago
- Cision Canada
Xanadu Selected for Prestigious Canadian Defence Program to Pioneer Next-Generation Battery R&D
TORONTO, July 30, 2025 /CNW/ - Xanadu, a global leader in quantum computing hardware and software, today announced its selection for Round 1 of the highly-competitive "IDEaS NORAD Modernization S&T Contest," an initiative by Innovation for Defence Excellence and Security (IDEaS) within Canada's Department of National Defence (DND). This selection underscores Xanadu's innovative capabilities in pioneering quantum algorithms for advanced battery design, a crucial step towards strengthening North America's defences against evolving aerospace and maritime threats, particularly in extreme environments. The IDEaS NORAD Modernization S&T Contest aims to foster groundbreaking solutions to modernize the science and technology portfolio of NORAD, the North American Aerospace Defense Command. Xanadu will receive an initial grant of $1,000,000 CAD to design quantum computing algorithms and methodologies for next-generation battery development. The goal is to advance the methods needed to design new batteries that are highly resilient to extreme conditions, including dramatic temperature changes, strong mechanical pressures, and radiation exposure. "We are honoured to be chosen for this groundbreaking program," said Juan Miguel Arrazola, Director of Quantum Algorithms. "Our work will focus on developing quantum algorithms to simulate battery mechanisms that lead to degradation performance under extreme conditions, such as ultra-low temperatures. The goal is to identify how quantum computers can lead to the development of more resilient batteries, unlocking new capabilities across defence, industry, and science." Xanadu's proposed project directly addresses two key IDEaS challenge topics: enhancing Arctic mobility and navigation of military platforms, and accelerating the development of quantum technologies. The Arctic is an increasingly important geostrategic region for North American defence, and current battery technologies struggle in its remote and extreme weather conditions, limiting the effectiveness of autonomous and remotely piloted systems. Xanadu's quantum-enabled simulations will help overcome the limitations of classical computing methods, enabling the design of batteries that can withstand these harsh environments. This project builds on Xanadu's extensive expertise and prior work in using quantum algorithms to simulate the design of new materials. This commitment to innovation will not only strengthen Canada's defence capabilities, but also enable breakthroughs with far-reaching implications for clean energy, transportation, and scientific exploration, demonstrating the transformative potential of quantum computing for a safer and more sustainable future. About Xanadu: Xanadu is a Canadian quantum computing company with the mission to build quantum computers that are useful and available to people everywhere. Founded in 2016, Xanadu has become one of the world's leading quantum hardware and software companies. The company also leads the development of PennyLane, an open-source software library for quantum computing and application development. Visit or follow us on X @XanaduAI. About the IDEaS NORAD Modernization S&T Contest: The Innovation for Defence Excellence and Security (IDEaS) program supports the ongoing evolution of continental defense capabilities by investing in researchers, innovators, and entrepreneurs. The NORAD Modernization S&T Contest specifically aims to assess new threats, evolve research and development, and co-develop technological solutions in immediate priority areas for North American defence. SOURCE Xanadu Quantum Technologies Inc.
Cision Canada
11 hours ago
- Cision Canada
FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025: SNAP BENEFITS LINKED TO SLOWER COGNITIVE DECLINE, 10-YEAR STUDY FINDS
Key Takeaways Participating in the Supplemental Nutrition Assistance Program (SNAP) may help protect against age-related cognitive decline, suggests an analysis of a national study. Compared to non-participants, SNAP participants had a slower decline in cognitive function during the 10-year study period, effectively maintaining an average of two to three additional years of cognitive health. Food insecurity can negatively impact cognitive function, and participating in SNAP may improve participants' diets and nutrition intake. TORONTO, July 30, 2025 /CNW/ -- People who participated in the U.S. Supplemental Nutrition Assistance Program (SNAP) had slower cognitive decline over 10 years than those who didn't participate, according to new research being reported today at the Alzheimer's Association International Conference ® 2025 (AAIC ®), in Toronto and online. The findings highlight the potential of food assistance programs to support cognitive health in the aging population and point to the need for additional efforts to reduce disparities in cognitive aging across different racial and ethnic groups, the researchers said. They also underscore the need for public health policies that ensure equitable access to programs like SNAP, which helps low-income individuals and families buy food, particularly for populations that may face additional barriers to enrollment. Using the nationally representative Health and Retirement Study (HRS), researchers compared participants in SNAP to those who were eligible for the program but didn't participate. They determined that SNAP participants had a 0.10% slower decline in overall cognitive function, or two to three additional years of cognitive health over the 10-year period. "Research has shown that food insecurity can negatively impact cognitive function, and this is one of the first long-term studies to show that food assistance programs can positively impact cognition," said Maria C. Carrillo, Ph.D., Alzheimer's Association chief science officer and medical affairs lead. "Simple, everyday actions can make a difference in brain health and may even lower the risk of Alzheimer's disease and dementia. The Alzheimer's Association is committed to helping all people build these habits into their daily lives, including eating right, one of our 10 Healthy Habits for Your Brain." Researchers analyzed a racially and ethnically representative group of people age 50 and older comparing 1,131 (average age ~63 years) who were enrolled in SNAP in 2010 to 1,216 who were eligible for SNAP but did not participate (average age ~66 years). Memory and executive function — the ability to plan and carry out tasks — were assessed every two years between 2010 and 2020 via telephone or web-based interviews. People with an initial cognition summary score indicating cognitive impairment or dementia (11 or less out of 27 points) were excluded from the analysis. While a 0.10-point difference in annual cognitive decline may seem small, the researchers note that its long-term impact is significant. "For someone starting at a healthy cognitive score, this slower decline could delay reaching the threshold for mild cognitive impairment by nearly a decade," said Linlin Da, MPH, lead author of the study and a Ph.D. candidate in health services research at the University of Georgia, Athens. "This suggests SNAP participation, or another similar nutrition support program, could significantly delay the onset of cognitive impairment or dementia, allowing people to preserve their ability to manage medications, finances and daily tasks longer," said Da. "This ultimately supports greater independence and higher quality of life in older adulthood." "At the same time, we discovered that this protective effect is not the same for everyone: non-Hispanic Black and Hispanic older adults did not benefit as much in cognitive functions compared to non-Hispanic white participants," Da added. Comparing the cognitive findings for White, Black and Hispanic SNAP participants in the study to their peers who didn't participate in SNAP, the researchers found all three groups benefitted, but observed much stronger benefits and slower decline for the White SNAP participants. "We hope health care providers will see that potentially delaying cognitive impairment is another reason to help their patients-in-need secure access to food assistance," said Suhang Song, Ph.D., corresponding author of the study and assistant professor in the department of health policy and management at the University of Georgia College of Public Health. About the Alzheimer's Association International Conference ® (AAIC ®) The Alzheimer's Association International Conference (AAIC) is the world's largest gathering of researchers from around the world focused on Alzheimer's and other dementias. As a part of the Alzheimer's Association's research program, AAIC serves as a catalyst for generating new knowledge about dementia and fostering a vital, collegial research community. AAIC 2025 home page: AAIC 2025 newsroom: AAIC 2025 hashtag: #AAIC25 About the Alzheimer's Association ® The Alzheimer's Association is a worldwide voluntary health organization dedicated to Alzheimer's care, support and research. Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia ®. Visit or call 800.272.3900. Linlin Da, MPH, et al. The association between Supplemental Nutrition Assistance Program participation and cognitive decline by racial/ethnic groups: a 10-year longitudinal study. (Funding: National Center for Advancing Translational Sciences of the National Institutes of Health UL1TR002378)
